Gene interactions and pathways from curated databases and text-mining
Immunopharmacology 2000, PMID: 10936515

Dexamethasone inhibits IL-1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation.

Jeon, Y J; Han, S H; Lee, Y W; Lee, M; Yang, K H; Kim, H M

In the present study, the mechanism by which dexamethasone (DEX) inhibited IL-1beta gene expression in bacterial lipopolysaccharide (LPS)-activated RAW 264.7 cells was investigated. The decrease in LPS-induced IL-1beta mRNA expression was demonstrated by quantitative reverse transcription polymerase chain reaction (RT-PCR). Since the promoter in IL-1beta gene contains binding motifs for NF-kappaB/Rel, AP-1, NF-IL6, and CREB/ATF, which appear to be important in LPS-mediated IL-1beta induction, the effects of DEX on the activation of these transcription factors were examined. Treatment of DEX to RAW 264.7 cells induced a dose-related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX. Treatment of RAW 264.7 cells with DEX inhibited DNA binding of NF-kappaB/Rel and AP-1 proteins to their cognate DNA sites as measured by electrophoretic mobility shift assay (EMSA). DEX treatment caused a significant reduction in nuclear c-rel, p65, and p50 protein contents, and these decreases were paralleled by the accumulation of cytoplasmic c-rel, p65, and p50. DEX treatment of RAW 264.7 cells did not inhibit the nuclear translocation of c-jun and c-fos. We found that the inhibition of IL-1beta production by DEX is not related to p38, which is important in the IL-1beta induction. These results suggest that DEX may inhibit IL-1beta gene expression by a mechanism involving the blocking of LPS-induced NF-kappaB/Rel and AP-1 activation.

Document information provided by NCBI PubMed

Text Mining Data

IL-1 beta → AP-1: " Dexamethasone inhibits IL-1 beta gene expression in LPS stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation "

IL-1 beta → NF-kappa B/Rel: " Dexamethasone inhibits IL-1 beta gene expression in LPS stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation "

IL-1 beta → B/Rel: " Dexamethasone inhibits IL-1 beta gene expression in LPS stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation "

IL-1beta → LPS: " The decrease in LPS induced IL-1beta mRNA expression was demonstrated by quantitative reverse transcription polymerase chain reaction ( RT-PCR ) "

IL-1beta → LPS: " Since the promoter in IL-1beta gene contains binding motifs for NF-kappaB/Rel, AP-1, NF-IL6, and CREB/ATF, which appear to be important in LPS mediated IL-1beta induction, the effects of DEX on the activation of these transcription factors were examined "

AP-1 → CREB/ATF: " Treatment of DEX to RAW 264.7 cells induced a dose related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX "

AP-1 → CREB/ATF: " Treatment of DEX to RAW 264.7 cells induced a dose related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX "

AP-1 → NF-IL6: " Treatment of DEX to RAW 264.7 cells induced a dose related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX "

NF-kappaB/Rel → CREB/ATF: " Treatment of DEX to RAW 264.7 cells induced a dose related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX "

NF-kappaB/Rel → CREB/ATF: " Treatment of DEX to RAW 264.7 cells induced a dose related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX "

NF-kappaB/Rel → NF-IL6: " Treatment of DEX to RAW 264.7 cells induced a dose related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX "

NF-kappaB/Rel → CREB/ATF: " Treatment of DEX to RAW 264.7 cells induced a dose related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX "

NF-kappaB/Rel → CREB/ATF: " Treatment of DEX to RAW 264.7 cells induced a dose related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX "

NF-kappaB/Rel → NF-IL6: " Treatment of DEX to RAW 264.7 cells induced a dose related inhibition of NF-kappaB/Rel and AP-1 in chloramphenicol acetyltransferase activity, while neither NF-IL6 nor CREB/ATF activation was affected by DEX "

AP-1 → NF-kappaB/Rel: " These results suggest that DEX may inhibit IL-1beta gene expression by a mechanism involving the blocking of LPS induced NF-kappaB/Rel and AP-1 activation "

AP-1 → NF-kappaB/Rel: " These results suggest that DEX may inhibit IL-1beta gene expression by a mechanism involving the blocking of LPS induced NF-kappaB/Rel and AP-1 activation "

NF-kappaB/Rel → LPS: " These results suggest that DEX may inhibit IL-1beta gene expression by a mechanism involving the blocking of LPS induced NF-kappaB/Rel and AP-1 activation "

NF-kappaB/Rel → LPS: " These results suggest that DEX may inhibit IL-1beta gene expression by a mechanism involving the blocking of LPS induced NF-kappaB/Rel and AP-1 activation "

Manually curated Databases

No curated data.